The Current Ratio as of November 2024 (TTM) for Allogene Therapeutics, Inc. (ALLO) is 9.35

According to Allogene Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 9.35. This represents a change of -20.08% compared to the average of 11.69 of the last 4 quarters.

Allogene Therapeutics, Inc. (ALLO) Historical Current Ratio (quarterly & annually)

How has ALLO Current Ratio performed in the past?

The mean historical Current Ratio of Allogene Therapeutics, Inc. over the last ten years is 11.46. The current 9.35 Current Ratio has changed 8.06% with respect to the historical average. Over the past ten years (40 quarters), ALLO's Current Ratio was at its highest in in the June 2020 quarter at 22.24. The Current Ratio was at its lowest in in the December 2017 quarter at 0.

Allogene Therapeutics, Inc. (ALLO) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Allogene Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Allogene Therapeutics, Inc. (ALLO) Average Current Ratio

How has ALLO Current Ratio performed in the past?

The current Current Ratio of Allogene Therapeutics, Inc. (ALLO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Allogene Therapeutics, Inc. (ALLO) Current Ratio vs. Peers

How is ALLO’s Current Ratio compared to its peers?

Allogene Therapeutics, Inc.’s Current Ratio is greater than G1 Therapeutics, Inc. (2.48), greater than Heron Therapeutics, Inc. (2.28), less than Annexon, Inc. (17.18), greater than Sangamo Therapeutics, Inc. (1.35), greater than Beam Therapeutics Inc. (5.69), greater than Sana Biotechnology, Inc. (4.47), greater than Caribou Biosciences, Inc. (7.38), greater than Editas Medicine, Inc. (3.75), less than Theseus Pharmaceuticals, Inc. (29.93), greater than aTyr Pharma, Inc. (6.07), less than Relay Therapeutics, Inc. (18.42), less than Century Therapeutics, Inc. (10.39), greater than Blueprint Medicines Corporation (3.32), greater than Intellia Therapeutics, Inc. (6.73), less than Verve Therapeutics, Inc. (13.05), greater than Prime Medicine, Inc. (6.50), less than iTeos Therapeutics, Inc. (14.80), less than Icosavax, Inc. (18.06), greater than Mirati Therapeutics, Inc. (7.54), greater than VectivBio Holding AG (9.14),

Build a custom stock screener for Allogene Therapeutics, Inc. (ALLO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Allogene Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Allogene Therapeutics, Inc. (ALLO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Allogene Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.